23 Feb 3 Growth Stocks to Watch In 2021!
T2 Biosystems, Inc. recently announced that its T2SARS-CoV-2™ Panel, a molecular diagnostic test that detects SARS-CoV-2, can detect the Brazil (P.1) variant of the SARS-CoV-2 virus. This expands the utility of its panel to reliably detect newer variants that have emerged in United Kingdom (B.1.1.7) and South Africa (B.1.351). The panel can provide results in under two hours and runs on the company’s T2MR-powered T2Dx® Instrument, the only FDA-cleared technology that can find low levels of pathogens in whole blood with as little as 1 CFU/mL. The product originally received an Emergency Use Authorization in the US in August 2020. Detection plays a very important role in prevention of COVID-19 and there is a great demand for faster and more efficient testing solutions.
T2 Biosystems, Inc. (NASDAQ: TTOO)
Market Cap: $372.85M; Current Share Price: 2.52 USD
Data by YCharts
The company’s T2 Magnetic Resonance (T2MR®) detection technology is the foundation of all of its diagnostic innovations. The method uses miniaturized magnetic resonance technology for direct detection and measurement of biomarkers, pathogens and other abnormalities in whole blood, plasma, serum, saliva, sputum, and urine. This novel method eliminates the need for purification or extraction of target molecules and can precisely identify molecular targets from the patient sample leading to a shortened diagnosis times and labor savings.
The Company’s T2Bacteria® Panel, is the only technology approved by the FDA, which can identify the bacteria responsible for sepsis from whole blood, without waiting for a blood culture. The time taken by the panel for species identification is merely 3 to 5 hours, as against 1 to 5 days taken by conventional methods. This helps healthcare providers to treat the infection in its early stages thereby improving the chances of survival and recovery. The biggest advantage of using this panel is that it is not affected by detection interference even when the patient is on antibiotics.
The company’s T2Candida Panel, is a direct-from-blood fungal pathogen detection assay that can help patients suffering from febrile neutropenia, septic shock, having LVAD or at an increased risk of developing candidemia, a condition whose mortality rate of 40% can be bought down to 11% by targeted treatment within 12 hours from the onset of infection. This method overcomes the limitation of the traditional candida diagnostic methods such as eliminating the need for a positive blood culture which are time consuming and inaccurate. It also helps reduce hospitalization costs by approximately $30,000 per patient by reducing the need for longer stay.
T2 has a strong pipeline of candidates that include T2Carba Resistance+ Panel a first-in-class detection panel that can identify gram-negative resistance markers such as Enterobacter and Klebsiella spp, developed in collaboration with Allergan and CARB-X. This has the potential to prevent the development of antibiotic resistance and arrest the spread of multidrug-resistant organisms.
In addition, it also has a T2Lyme Panel under development in partnership with Canon U.S. Life Sciences that can accurately detect the bacteria that cause Lyme disease and T2Candida auris Panel RUO that can detect emerging superbug in patient skin, blood and hospital environmental samples.
T2 biosystems has shown some impressive results in cost savings for both hospitals as well as patients as part of its stewardship program with institutions such as UPMC, Henry Ford Health System, Lee Health, Huntsville Hospital, Robert Wood Johnson Medical School, Riverside Community Hospital to name a few.
Diagnosis plays a key role in the accurate detection and treatment of Sepsis, the Company’s area of expertise, and will see a CAGR of 9.1% to reach an estimated USD 613.9 Million by 2023 from USD 396.6 Million in 2018, according to a report by marketsandmarkets.
Market Cap: $1.98B; Current Share Price: 75.40 USD
Data by YCharts
DermTech aims to redefine the way skin cancer is detected, by leveraging its non-invasive skin genomics platform. The Company’s Pigmented Lesion Assay/PLA can lift the skin’s RNA material, eliminating the need of a scalpel. The test provides utmost accuracy with almost 99% negative predictive value and has the ability to see 10,000x further into a cell compared to a conventional biopsy. The samples are analyzed in a state-of-the-art custom built lab Gene Lab, where they undergo an automated amplification process called RT-PCR, to study the presence of RNA molecules, specifically genes that are predictive of melanoma, namely PRAME and LINC00518.
The test has made it to the National Comprehensive Cancer Network (NCCN) guidelines, an alliance of 30 cancer centres across the U.S, that suggests that non-invasive PLA test can help Doctors decide if a biopsy is required. In addition, the PLA is now being covered by Medicare, Blue Cross and Blue Shield (in the States of Texas, Illinois and California) and Geisinger Health Plans in Pennsylvania boosting its reimbursements rates. The Company is trying to forge partnerships with telemedicine health providers and other entities, to offer its products as part of a PLA collection kit, to enhance its customer base.
Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,230 deaths every year as per an estimate by the American Cancer Society, these numbers are steadily rising over the years with approximately 96,480 new melanomas diagnosis being made each year. WHO places the global incidences of melanoma at 132,000 new diagnoses made each year.
A report by Globaldata predicts the global treatment market for melanoma to reach $5.64 billion by 2023 from $1.34 billion in 2013 with a CAGR of 15.5%. The major drivers for growth in the market would be the expanding treatment options to include targeted combination therapies, deteriorating environmental condition leading to higher exposure to UV rays, favorable government and regulatory environment, patent expiration of certain biosimilars and launch of generics that are expected to pave the way for new players to enter the market.
DermTech’s technology is being evaluated in Phase 1 – 3 trials to support the discovery and development of programs in cancers and inflammatory diseases that involve skin as a target organ. Some of these indications include GVHD, Alopecia Areata, Psoriasis, Vitiligo to name a few. Dermtech’s Pharma and Lab partners are industry leading organizations such as AstraZeneca (NASDAQ: AZN), Biogen (NASDAQ: BIIB), Covance, abbvie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ).
Furthermore, the Company’s pipeline consists of development of a Carcinome test for the early detection of non-melanoma skin cancers at the genomic level and LuminateSM, a test to identify UV damage at the genomic level. LuminateSM is looking at a potential approval in first half of 2022 and will be marketed directly to customers in the form of an at-home test.
Market Cap: $315.31M; Current Share Price: 14.88 USD
Data by YCharts
Soliton’s Rapid Acoustic Pulse (RAP) device is a path-breaking acoustic shockwave technology that has received FDA approval for temporary reduction in the appearance of cellulite. The technology had earlier received a 510(k) clearance from the FDA for tattoo removal in 2019 and will be available for sale in the first half of 2021.
The technology addresses a very important need for a fast, painless and economical treatment option for treatment of cellulite and tattoo removal. Currently the treatment for both procedures is surgical in nature and involve considerable side-affects, downtime and repeated clinical visits. The Rap device can disrupt fibrotic septa that connects dermis to the muscle layer without breaking the skin and offers multiple advantages such as tolerability, minimal collateral damage, no anesthesia or downtime.
The Company believes that the product can disrupt an $18 billion-dollar global market for tattoo removal, cellulite reduction and keloid scar treatment. Soliton has built a robust patent portfolio of over 9 patent families filed and has obtained a Worldwide exclusive license from MD Anderson.
Soliton’s pipeline consists of Keloid and Hypertrophic Scar Reduction and Skin Laxity Reduction and the Company is also exploring potential treatment of Fibrosis. However, the impact of COVID-19 on the aesthetic market has been significant with cosmetic dermatologists closing operations due to lockdowns, this has prompted the Company to revise its commercial launch and financing strategy. The Company is eyeing a potential commercial launch of its Tattoo and Cellulite treatment in H1,2021.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Click here to please visit our detailed disclosure